Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ambulatory adults aged 50 years and older~2. Medically stable, as determined by medical history and targeted physical examination based on medical history, if appropriate~3. Able to understand and comply with planned study procedures~4. Provides written informed consent prior to initiation of any study procedure.~Exclusion Criteria:~1. Known contraindication to either study vaccine (see product package inserts)~2. Receipt of any other influenza or other vaccine within 30 days prior to enrollment in this study.~3. Receipt of any new medication within 30 days prior to enrollment in this study~4. Plans to participate in any investigation involving an investigational product during this study.~5. Pre-existence of atopic dermatitis or any other cutaneous disorder that could complicate the evaluation of potential primary endpoints.~6. Any clinical or social circumstance that in the opinion of the investigator could interfere with compliance with study procedures or interfere with the interpretation of clinical data.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Flublok (Type: ACTIVE_COMPARATOR): Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
- Afluria (Type: PLACEBO_COMPARATOR): Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).